Themis Medicare partners with NFL Biosciences to develop NFL-101

07 Oct 2022 Evaluate

Themis Medicare has entered into a partnership to develop NFL-101 with NFL Biosciences (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, the company’s drug candidate for smoking cessation, for the Indian market.

Themis Medicare submitted an IND (Investigational New Drug) application for a Phase II / III clinical trial to the Central Drugs Standard Control Organization (CDSCO), the National Regulatory Authority of India (NRA). India has approximately 267 Million smokers, and their options for smoking cessation are very limited.

Once the study is approved, the clinical trial will be conducted in India, targeting 334 smokers. The cost of the process, from submission to completion of the study, will be carried out by Themis Medicare. Themis Medicare will purchase from NFL Biosciences NFL-101 Active Pharmaceutical Ingredient (API). NFL will also receive double digit royalties on sales.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×